Walleye Capital LLC Has $3.27 Million Position in Abeona Therapeutics Inc (NASDAQ:ABEO)

Walleye Capital LLC lessened its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 31.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 586,250 shares of the biopharmaceutical company’s stock after selling 275,051 shares during the quarter. Walleye Capital LLC’s holdings in Abeona Therapeutics were worth $3,265,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics in the third quarter valued at about $84,000. Charles Schwab Investment Management Inc. acquired a new stake in Abeona Therapeutics in the 3rd quarter worth about $151,000. XTX Topco Ltd acquired a new position in shares of Abeona Therapeutics during the 3rd quarter worth approximately $160,000. Trexquant Investment LP bought a new position in shares of Abeona Therapeutics during the fourth quarter worth approximately $382,000. Finally, JPMorgan Chase & Co. grew its position in Abeona Therapeutics by 74.2% during the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 28,606 shares in the last quarter. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ABEO shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday, March 24th. Oppenheimer began coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target for the company. Finally, StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 24th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.50.

Insider Buying and Selling

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 25,000 shares of the business’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the sale, the chief executive officer now owns 1,355,322 shares of the company’s stock, valued at approximately $6,478,439.16. The trade was a 1.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 33,000 shares of company stock worth $161,420 in the last three months. 5.40% of the stock is owned by corporate insiders.

Abeona Therapeutics Trading Down 0.2 %

Shares of ABEO opened at $4.84 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics Inc has a 52-week low of $3.05 and a 52-week high of $8.17. The firm has a market cap of $236.19 million, a price-to-earnings ratio of -1.80 and a beta of 1.71. The business’s fifty day moving average is $5.13 and its 200-day moving average is $5.68.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.19. Equities analysts anticipate that Abeona Therapeutics Inc will post -1.16 EPS for the current fiscal year.

Abeona Therapeutics Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.